9 results about "Clear cell carcinoma" patented technology

The application provides a polymer carbon nitride@Hittorf red phosphorus heterostructure and application thereof in preparation of a medicine for targeted treatment of renal clear cell carcinoma, and belongs to the technical field of nano medicines. The application designs a near-infrared light response Hittorf red phosphorus (HP) modified polymer carbon nitride heterostructure (PCN@HP) based on a simple chemical vapor deposition (CVD) method. Experimental research finds that the HP nanorods vertically grown on the PCN exhibit wide and strong light absorption in the near-infrared range. In-vivo and in-vitro experiments prove that under near-infrared light irradiation, when the concentration of the suspension is 100 μg / mL, the tumor inhibition rate reaches 100%. Notably, the composite has no damage to normal tissues and cells, but it has obvious targeted inhibition effect on deep ccRCC cells in the body. In addition, the composite material has good biocompatibility and spontaneous light effect, and can be completely metabolized in the body within 48 hours, and is a kind of nanoparticle with imaging and PDT / PTT synergistic treatment, and can be used for efficient tumor nano treatment.

This invention discloses the application of urinary microvesicle proteins as diagnostic markers for renal cell carcinoma. The protein markers derived from urinary extracellular vesicles associated with clear cell renal carcinoma are characterized by being selected from one or more of the following proteins: CSPG4, AQP1, PLIN2, CA9, and HAVCR1. The invention also describes the application of reagents for detecting these protein markers in the preparation of auxiliary diagnostic reagents for clear cell renal carcinoma. The inventors, using flow cytometry, analyzed 200 patients and found that five proteins derived from urinary extracellular vesicles could effectively distinguish patients with clear cell renal carcinoma from controls (including healthy individuals, patients with benign renal tumors, patients with benign renal cysts, and patients with chronic kidney disease).

The invention provides application of an MASP1 marker in preparation of a product for diagnosing and evaluating prognosis condition of renal clear cell carcinoma, and belongs to the technical field of renal clear cell carcinoma markers. Researches find that MASP1 expression in renal clear cell carcinoma tissues is significantly reduced, and the MASP1 expression level has significant correlation with good clinical prognosis of renal clear cell carcinoma patients. After MASP1 expression is inhibited, the level of branched chain amino acid in renal clear cell carcinoma cells is remarkably increased, key enzymes of related pathways are changed, end products of the renal clear cell carcinoma cells are accumulated, and metabolites generated after MASP1 inhibition have remarkable correlation with poor clinical prognosis of renal clear cell carcinoma patients. The MASP1 is used as a marker for diagnosing and evaluating the prognosis condition of the patient with the clear cell carcinoma of kidney, and has high sensitivity and specificity.

The invention belongs to the technical field of biological medicine, and discloses a method for analyzing an action target of artemisinin for treating renal clear cell carcinoma based on network pharmacology and a molecular docking technology, and the method comprises the following steps: S1, screening the action target of an artemisinin active component; s2, identifying candidate disease targets; s3, acquiring an intersection target point; s4, constructing a protein-protein interaction network and performing network topology analysis; s5, core target biological function and molecular action signal path analysis and visualization; s6, constructing an artemisinin-renal clear cell carcinoma-target spot-pathway network diagram; s7, exploring an action mechanism of artemisinin for improving the renal clear cell carcinoma based on a molecular docking technology; s8, carrying out survival analysis on the core target spot based on the TCGA database, and drawing a Kaplan-Meier curve; and S9, observing the influence of artemisinin and derivatives thereof on the activity of renal clear cell carcinoma 786-O cells by adopting a CCK-8 method. Network pharmacology and molecular docking technologies are applied, multiple omics data are integrated from the perspective of system biology, a drug-target-disease network is constructed, the interaction between artemisinin and renal clear cell carcinoma related targets is deeply analyzed, and the action mechanism of artemisinin on the aspects of genes, proteins, signal channels and the like is comprehensively revealed.

The invention relates to application of a PELI2 gene as a molecular marker of renal clear cell carcinoma. The nucleotide sequence of the PELI2 gene is as shown in SEQ ID NO. 1. It is found for the first time that the PELI2 gene is remarkably low in expression in renal clear cell carcinoma cells, and the expression level of the PELI2 gene is closely related to prognosis of patients. The expression of the PELI2 gene in the renal clear cell carcinoma cells is remarkably reduced, and the survival rate of a renal cancer patient with high expression of the PELI2 gene is remarkably higher than that of a renal cancer patient with low expression of the PELI2 gene. Meanwhile, experiments prove that the proliferation capacity of renal clear cell carcinoma cells can be inhibited by overexpression of the PELI2 gene. On the basis, a primer pair capable of specifically recognizing the PELI2 gene and an overexpression lentivirus of the PELI2 gene are designed, and the application of the PELI2 gene as a marker in diagnosis and prognosis evaluation of the renal clear cell carcinoma and targeted therapy of the renal clear cell carcinoma is provided, which is of great significance in subsequent drug research of the renal clear cell carcinoma.

Provided herein are methods and compositions for reducing the expression and / or activity of an oncogenic transfer RNA (tRNA). Composition for treating cancer in the subject are disclosed, comprising an inhibitor of an oncogenic transfer RNA (tRNA) to a subject in need thereof, wherein the oncogenic tRNA comprises an inhibitory nucleic acid such as ARG-TCT-4-1, an siRNA, an shRNA, an miRNA, an antisense oligonucleotide, or a nucleic acid modification such as a locked nucleic acid, a phosphorothioate modification, a 2′—O-methyl modification, a 2′—O-methoxyethyl modification, a 2′-fluoro modification, a phosphorodiamidate modification, or a mesylphosphoramidate modification. The disclosed compositions are disclosed as treating cancers such as a sarcoma, a glioblastoma, an adrenocortical carcinoma, a cholangiocarcinonma, a melanoma, a glioma, a diffuse glioma, a mature B cell neoplasm, a non-small cell lung cancer, an esophagogastric adenocarcinoma, a pheochromocytoma, a hepatocellular carcinoma, an endometrial carcinoma, a pancreatic adenocarcinoma, a breast carcinoma, an invasive breast carcinoma, a head and neck squamous cell carcinoma, a bladder urothelial carcinoma, a colorectal adenocarcinoma, an ovarian epithelial tumor, a prostate adenocarcinoma, a cervical squamous cell carcinoma, a renal non-clear cell carcinoma, or a renal clear cell carcinoma.

The application belongs to the field of biological medicine, and discloses a targeting HLA-G / CD70 bispecific CAR-T cell and application thereof. The inventors obtain a mutant with significantly improved affinity to HLA-G by mutating the natural receptor ILT4 protein of HLA-G, so that the HLA-G single-target CAR-T constructed by the mutant has stronger tumor killing ability. The bispecific CAR-T cell constructed by using the ILT4 mutant as the HLA-G binding domain and connecting the CD70 binding domain can efficiently cover tumors with high expression of HLA-G / CD70, such as heterogeneous renal clear cell carcinoma, overcome tumor antigen heterogeneity, strengthen the targeted synergistic killing efficiency, eliminate the self-killing defect of the CAR-T cell, delay the exhaustion and apoptosis of the CAR-T cell in the body, and long-term inhibit tumor recurrence.

The application provides a use of an NR2F2 agonist levomilnacipran in preparation of a drug for treating female renal clear cell carcinoma (ccRCC). In an estrogen environment, the levomilnacipran can significantly promote expression of NR2F2, and significantly inhibit proliferation, invasion and migration of ccRCC cells. The levomilnacipran can be used as a novel therapeutic drug for female ccRCC, and can specifically inhibit progression of the female ccRCC, and has important significance for disease prognosis.

The invention belongs to the technical field of biological medicines, and discloses an application of ACSS1 as a target in screening / preparing a medicine for treating renal clear cell carcinoma, and an application of a reagent for inhibiting expression of ACSS1 in preparing a medicine for treating renal clear cell carcinoma. The invention also discloses application of a reagent for detecting ACSS1 expression in preparation of a kit for diagnosing renal clear cell carcinoma or prognosis of renal clear cell carcinoma. Experiments prove that by knocking down ACSS1, the expression level of a tyrosine kinase receptor EphA2 can be lowered, growth of the renal clear cell carcinoma is inhibited, a new target is provided for treatment of the renal clear cell carcinoma, PI3K / AKT / mTOR pathway activation can be inhibited by inhibiting EphA2, then proliferation, migration and metabolism of cells are regulated and controlled, and therefore the purpose of relieving or treating the renal clear cell carcinoma is achieved. The invention provides a new direction and thought for the treatment of the clear cell renal carcinoma, and is expected to be applied to the research and development of new drugs for treating the clear cell renal carcinoma.